# Dual Antiplatelet Therapy After PCI

Select DAPT duration after PCI by first separating ACS from chronic coronary syndrome, then weighing bleeding risk, oral anticoagulation, and residual ischemic or procedural risk. Short DAPT followed by P2Y12 monotherapy is appropriate in selected patients; 12 months remains the ACS default.

**Clinical question:** How should clinicians individualize dual antiplatelet therapy duration after PCI with contemporary drug-eluting stents?

Updated: 2026-09-15T17:46:50.061407+00:00

## What matters in practice
- After PCI for ACS, 12 months of aspirin plus a potent P2Y12 inhibitor remains the default strategy; shorten therapy only after an explicit ischemic-versus-bleeding assessment. [1][15][18]
- For chronic coronary syndrome PCI without high bleeding risk, the conventional regimen is 6 months of aspirin plus clopidogrel; selected patients with noncomplex PCI and low ischemic risk may receive shorter DAPT. [11][15]
- A PRECISE-DAPT score of 25 or greater identifies high bleeding risk; in pooled randomized data, prolonged DAPT increased bleeding without incremental ischemic benefit even after complex PCI. [2][4]
- In PCI patients requiring long-term oral anticoagulation, stop aspirin after 1 to 4 weeks of triple therapy and continue oral anticoagulation plus a P2Y12 inhibitor rather than prolonged triple therapy. [3]
- Do not use immediate aspirin-free antiplatelet therapy after PCI as routine de-escalation; data indicate potential harm, particularly in ACS. [16]

## Set the default duration from the PCI presentation

Classify the index presentation before modifying duration for bleeding or ischemic risk.

For ACS treated with PCI, begin with a planned 12-month course of DAPT using aspirin plus a potent P2Y12 inhibitor, ticagrelor or prasugrel, unless bleeding risk, an oral-anticoagulation indication, or a competing contraindication changes the net clinical balance. ACS guidance and contemporary summaries continue to identify 12 months as the default; clopidogrel is generally reserved when ticagrelor or prasugrel cannot be used or when bleeding risk is high. [1][10][15][18]

For PCI performed for chronic coronary syndrome, use aspirin plus clopidogrel for a conventional 6-month course in patients without high bleeding risk. Consider an abbreviated course in noncomplex PCI when ischemic risk is reasonable, there is no substantial residual coronary disease, and the bleeding consequence of continuing DAPT outweighs expected ischemic protection. [11][15]

The duration decision is not determined by stent type alone. Contemporary drug-eluting stent safety and randomized trials support 1- to 3-month DAPT followed by P2Y12 inhibitor monotherapy in selected patients, and the 2021 ACC/AHA/SCAI revascularization guideline assigned this approach a class IIa recommendation after stent implantation in stable CAD and ACS. This option requires a planned transition rather than unstructured early discontinuation of either agent. [12]
- ACS PCI: plan 12 months of DAPT first; then test whether bleeding risk or anticoagulation justifies abbreviation. [1][15][18]
- Chronic coronary syndrome PCI: 6 months of aspirin plus clopidogrel is the conventional starting plan. [11][15]
- Do not extrapolate the favorable short-DAPT evidence to cessation of antiplatelet therapy immediately after PCI. [16]

*Initial DAPT-duration framework after contemporary DES PCI. [11][12][15][16][18]*

| Clinical setting | Default antiplatelet strategy | When a shorter strategy is most defensible | Important limitation |
| --- | --- | --- | --- |
| ACS treated with PCI | Aspirin plus ticagrelor or prasugrel for 12 months. [1][15][18] | Selected patients after 1 to 3 months of event-free DAPT when bleeding risk predominates; P2Y12 inhibitor monotherapy is the studied de-escalation approach. [12][19] | One-month DAPT followed by clopidogrel showed a possible excess of net adverse ischemic events in ACS in STOPDAPT-2. [17] |
| Chronic coronary syndrome treated with PCI | Aspirin plus clopidogrel for 6 months. [11][15] | Noncomplex PCI, reasonable ischemic profile, and no substantial residual coronary disease support considering shorter DAPT. [15] | Assess procedural and patient-level ischemic risk before abbreviating therapy. [15] |
| PCI with immediate aspirin-free strategy | Not a routine strategy. [16] | None established by the cited trial evidence. [16] | Immediate post-PCI prasugrel monotherapy was not beneficial and may be harmful, especially in ACS. [16] |

## Use high bleeding risk to shorten DAPT despite PCI complexity

Quantify bleeding risk before extending therapy for anatomy or presentation alone.

Calculate the PRECISE-DAPT score when duration is uncertain. A score of 25 or greater defines high bleeding risk in the cited pooled analysis. Among 14,963 PCI patients from eight randomized trials, prolonged DAPT reduced ischemic events in patients with PRECISE-DAPT scores below 25, including those undergoing complex PCI, but increased bleeding in patients with scores of 25 or greater without additional ischemic benefit. [2][4]

In patients meeting high-bleeding-risk criteria, 1- or 3-month DAPT after PCI lowered major or clinically relevant bleeding, major bleeding, and cardiovascular mortality compared with standard-duration DAPT in a randomized-trial meta-analysis. Ischemic outcomes, including MACE and stent thrombosis, were similar across abbreviated and standard-duration strategies, although patients receiving oral anticoagulation were excluded from that meta-analysis. [8]

Choose the single-antiplatelet agent after abbreviated DAPT deliberately. In high-bleeding-risk trial populations, aspirin or a P2Y12 inhibitor as monotherapy after short DAPT had no observed difference in bleeding or ischemic protection in the meta-analysis; however, P2Y12-monotherapy evidence varies by the agent, clinical presentation, and trial design. [8]
- PRECISE-DAPT 25 or greater: treat bleeding risk as the dominant duration modifier, including after complex PCI. [2][4]
- PRECISE-DAPT below 25: complex PCI and other ischemic features can support avoiding an overly abbreviated course when bleeding risk remains low. [2][4]
- Do not treat oral anticoagulation as interchangeable with other high-bleeding-risk criteria when applying short-DAPT trial results; oral-anticoagulated patients were excluded from the cited high-bleeding-risk meta-analysis. [8]

### When longer DAPT remains reasonable

If bleeding risk is low, the ischemic benefit of prolonged DAPT is most relevant in patients with greater baseline ischemic risk, including complex PCI. In the DAPT trial, continuing a P2Y12 inhibitor plus aspirin from 12 to 30 months reduced overall ischemic events by 29% and stent thrombosis by 71%, but increased bleeding by 61%; benefit attenuated and bleeding increased with advancing age. [6]

Avoid extending DAPT simply because PCI was complex if PRECISE-DAPT is 25 or greater. In pooled data, high bleeding risk neutralized the incremental ischemic advantage of a long DAPT course and produced an unfavorable net clinical outcome. [2]

*Risk features that change the DAPT-duration decision. [2][4][6][8]*

| Finding | Interpretation | Duration implication |
| --- | --- | --- |
| PRECISE-DAPT score <25 | Non-high-bleeding-risk group in pooled randomized analyses. [2][4] | Do not abbreviate solely because of PCI complexity; extended therapy can reduce ischemic events when bleeding risk remains low. [2][4] |
| PRECISE-DAPT score ≥25 | High bleeding risk. [2][4] | Favor abbreviated DAPT; prolonged DAPT increased bleeding without added ischemic benefit even with complex PCI. [2][4] |
| Complex PCI with low bleeding risk | Higher ischemic-event risk than noncomplex PCI. [2] | Consider avoiding a short course when the anticipated ischemic benefit exceeds bleeding liability. [2][4] |
| Older age | Extended-DAPT efficacy benefit is attenuated while bleeding rises with age. [6] | Reassess the net benefit before continuing DAPT beyond 12 months. [6] |

## Limit triple therapy when long-term oral anticoagulation is required

Separate patients requiring chronic anticoagulation from standard DAPT pathways.

For a patient undergoing PCI who also requires long-term oral anticoagulation, use only a brief period of triple therapy with aspirin, a P2Y12 inhibitor, and oral anticoagulation. Stop aspirin after 1 to 4 weeks, then continue oral anticoagulation plus a P2Y12 inhibitor. This is a class I recommendation cited for PCI patients receiving oral anticoagulation. [3]

The rationale is clinically consequential: triple antithrombotic therapy has been associated with greater than a threefold increased major-bleeding risk. Compared with prolonged triple therapy, oral anticoagulation plus a P2Y12 inhibitor reduces bleeding without compromising death or MI in the cited evidence base, although meta-analysis data suggest that very early aspirin discontinuation may increase stent thrombosis. [3][9]

Before shortening triple therapy toward the earliest end of the 1- to 4-week interval, explicitly weigh early stent-thrombosis concern against bleeding liability. The extent of the potential stent-thrombosis tradeoff in high-bleeding-risk patients requiring oral anticoagulation remains uncertain; avoid applying non-anticoagulated short-DAPT results directly to this group. [3][8]
- Long-term oral anticoagulation after PCI: aspirin plus P2Y12 inhibitor plus anticoagulant for 1 to 4 weeks, then discontinue aspirin. [3]
- Avoid prolonged triple therapy because major bleeding risk is substantially amplified. [9]
- Document why aspirin is stopped at 1 week versus continued toward 4 weeks when ischemic and bleeding risks compete. [3]

*Antithrombotic transition in PCI patients requiring long-term oral anticoagulation. [3][9]*

| Post-PCI interval | Regimen | Decision point |
| --- | --- | --- |
| Immediately after PCI through 1 to 4 weeks | Triple therapy: aspirin, a P2Y12 inhibitor, and oral anticoagulation. [3] | Use the shortest interval consistent with the individual ischemic and bleeding balance. [3] |
| After the initial 1- to 4-week interval | Oral anticoagulation plus a P2Y12 inhibitor; stop aspirin. [3] | Avoid extending triple therapy solely by habit; bleeding rises substantially with triple therapy. [9] |

## Choose a validated short-DAPT transition rather than indiscriminate early withdrawal

The timing and the agent continued after DAPT determine whether a short strategy matches trial evidence.

For selected patients undergoing PCI, a 1- to 3-month DAPT course followed by P2Y12 inhibitor monotherapy is the principal abbreviated strategy reflected in U.S. revascularization guidance. In ACS patients undergoing DES PCI, a network meta-analysis found that 1 month of DAPT followed by potent P2Y12 inhibitor monotherapy reduced major bleeding without increasing MACCE compared with 12 months of DAPT. [12][19]

Ticagrelor-based evidence is strongest for patients who complete an initial 3-month DAPT period. In TWILIGHT, 3 months of DAPT followed by ticagrelor monotherapy reduced clinically relevant bleeding versus continued ticagrelor plus aspirin without increasing death, MI, or stroke; the finding was confirmed in patients aged 65 years or older. [7]

Do not assume that every short-DAPT regimen is equivalent in ACS. STOPDAPT-2 found lower bleeding with 1 month of DAPT followed by clopidogrel monotherapy, but identified a possible interaction suggesting excess net adverse ischemic events among ACS patients. This makes 1-month clopidogrel monotherapy a less secure default for unselected ACS PCI than a potent P2Y12-monotherapy strategy. [17][19]

Avoid immediate substitution of DAPT with P2Y12 monotherapy at the time of PCI. In STOPDAPT-3, immediate prasugrel monotherapy was not beneficial and could be harmful, particularly in ACS; DAPT remained the standard during the first month after coronary stent implantation. [16]
- After 3 event-free months of ticagrelor-based DAPT in an appropriate high-risk PCI patient, ticagrelor monotherapy reduces clinically relevant bleeding without an observed increase in death, MI, or stroke. [7]
- After 1 month of DAPT, distinguish potent P2Y12-monotherapy evidence in ACS from clopidogrel-based strategies, which have more uncertain ACS ischemic safety. [17][19]
- Do not discontinue aspirin immediately after PCI as a routine aspirin-free strategy. [16]

### Use response to therapy as a gate before de-escalation

The short-DAPT trials informing monotherapy strategies generally transition patients after a defined initial DAPT interval rather than during the acute procedural period. At the planned transition visit, confirm absence of interval ischemic events, assess clinically relevant bleeding, reconcile adherence, and re-evaluate whether the original ischemic-versus-bleeding assessment still applies before stopping one agent. The trial timing itself is a safety boundary: 1 month for selected protocols and 3 months for ticagrelor monotherapy in TWILIGHT. [7][12][16]

*Evidence-informed abbreviated DAPT pathways after PCI. [7][12][16][17][19]*

| Strategy | Population signal | Observed tradeoff | Use boundary |
| --- | --- | --- | --- |
| 1 month DAPT then potent P2Y12 inhibitor monotherapy | ACS PCI network meta-analysis. [19] | Less major bleeding without increased MACCE versus 12-month DAPT. [19] | Use a potent P2Y12-based approach rather than assuming clopidogrel data are interchangeable. [17][19] |
| 3 months DAPT then ticagrelor monotherapy | High-risk PCI patients in TWILIGHT, including ACS and older-patient analyses. [7] | Lower clinically relevant bleeding without increased death, MI, or stroke. [7] | Apply after completion of the initial 3-month DAPT phase. [7] |
| 1 month DAPT then clopidogrel monotherapy | Mixed stable and unstable PCI population in STOPDAPT-2. [17] | Lower TIMI major/minor bleeding; possible excess net adverse ischemic events in ACS. [17] | Do not make this the default abbreviated strategy for unselected ACS. [17] |
| Immediate prasugrel monotherapy after PCI | STOPDAPT-3. [16] | Not beneficial and potentially harmful, especially in ACS. [16] | Avoid as routine post-PCI de-escalation. [16] |

## Reassess DAPT at 1, 3, 6, and 12 months rather than auto-renewing therapy

Each time landmark should trigger a new risk-benefit decision.

At 1 month, determine whether the patient is on a planned high-bleeding-risk or oral-anticoagulation pathway. For patients requiring oral anticoagulation, aspirin should be stopped no later than the individualized 1- to 4-week triple-therapy interval. For non-anticoagulated patients, do not interpret the 1-month landmark as universal permission to stop DAPT; ACS phenotype, P2Y12 agent, and ischemic risk remain decisive. [3][16][17][19]

At 3 months, reassess candidacy for P2Y12 monotherapy when bleeding risk is clinically important and the initial DAPT course has been completed without an ischemic event. Ticagrelor monotherapy after 3 months of DAPT reduced clinically relevant bleeding without an observed ischemic penalty in TWILIGHT. [7]

At 6 months, chronic coronary syndrome patients have reached the conventional DAPT endpoint. Continue beyond that point only when ischemic protection is expected to outweigh bleeding risk; extended therapy has its clearest rationale in low-bleeding-risk patients with higher ischemic risk. [11][15]

At 12 months after ACS, do not automatically extend DAPT. Extension to 30 months reduced ischemic events and stent thrombosis in the DAPT trial but increased bleeding; the balance becomes less favorable with older age and with PRECISE-DAPT-defined high bleeding risk. [2][6]
- At every transition, document index presentation, PRECISE-DAPT category when available, oral-anticoagulation status, interval ischemic events, interval bleeding, and the planned single-agent regimen. [2][3][7]
- Escalate away from an abbreviated plan if an ischemic event occurs during the intended initial DAPT phase; the cited short-DAPT evidence applies to planned transitions after defined treatment intervals. [7][12][16]
- Avoid extension beyond 12 months in patients with PRECISE-DAPT score 25 or greater solely because PCI was complex. [2][4]

*Practical reassessment landmarks after PCI. [2][3][6][7][11][15][16]*

| Time point | Required decision | Potential action |
| --- | --- | --- |
| 1 month | Is chronic oral anticoagulation required, and is a validated abbreviated pathway intended? [3][16] | Stop aspirin in oral-anticoagulated patients after 1 to 4 weeks of triple therapy; do not routinely use immediate or universal aspirin-free treatment. [3][16] |
| 3 months | Does bleeding risk now justify ticagrelor monotherapy after event-free initial DAPT? [7] | Consider stopping aspirin and continuing ticagrelor in an appropriate patient. [7] |
| 6 months | Was PCI for chronic coronary syndrome, and is there a reason to continue DAPT? [11][15] | Complete conventional DAPT unless low bleeding risk and higher ischemic risk support continuation. [11][15] |
| 12 months | Was PCI for ACS, and is extension net beneficial? [6][18] | Stop DAPT or extend only after reweighing ischemic benefit against bleeding, particularly in older patients or those with PRECISE-DAPT ≥25. [2][6] |

## References
1. Short-Term Dual Antiplatelet Therapy After Drug-Eluting Stenting in ... — jamanetwork.com — https://jamanetwork.com/journals/jamacardiology/fullarticle/2824179
2. Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2018.11.048
3. Short Dual Antiplatelet Therapy in High Bleeding Risk Patients: 1 Month or 3 Months?∗  | JACC: Cardiovascular Interventions — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jcin.2023.08.037
4. Twilight, the Dawn of a New Era of Aspirin-Free PCI?∗ | JACC — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2020.03.071
5. Combined effect of D-dimer, hs-CRP, and Lp(a) on 5-year clinical ... — www.cell.com — https://www.cell.com/iscience/pdf/S2589-0042(23)01107-0.pdf
6. Antithrombotic Management of Elderly Patients With Coronary Artery Disease — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jcin.2021.01.040
7. De-escalation or abbreviation of dual antiplatelet therapy in acute ... — www.nature.com — https://www.nature.com/articles/s41569-023-00901-2
8. Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials | European Heart Journal | Oxford Academic — academic.oup.com — https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehac706/6881138?redirectedFrom=fulltext
9. Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI — academic.oup.com — https://academic.oup.com/ehjcvp/article/8/3/216/6015238
10. Individualization of Duration of Dual Antiplatelet Therapy after Coronary Stenting: A Comprehensive, Evidence-Based Review — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10672070
11. Antiplatelet Therapy in Chronic Coronary Artery Disease Patients With a History of Angioplasty. When is Aspirin Not Enough? A Systematic Review - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC12516749
12. Shortened Duration of Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention: A Contemporary Clinical Review — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10782423
13. Demystifying Antiplatelet Therapy Duration Following Percutaneous ... — www.acc.org — https://www.acc.org/latest-in-cardiology/articles/2025/12/08/18/14/demystifying-antiplatelet-therapy
14. Clopidogrel versus aspirin monotherapy following dual antiplatelet therapy after percutaneous coronary intervention: an updated meta-analysis of 162,829 patients — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC12881014
15. Dual antiplatelet therapy for the general cardiologist: recent ... — www.escardio.org — https://www.escardio.org/communities/councils/cardiology-practice/education/cardiopractice/dual-antiplatelet-therapy-for-the-general-cardiologist-recent-evidence-balanci
16. Short and Optimal Duration of Dual Antiplatelet Therapy After Everolimus-Eluting Cobalt-Chromium Stent-3 - American College of Cardiology — www.acc.org — https://www.acc.org/latest-in-cardiology/clinical-trials/2023/08/24/00/08/stopdapt-3
17. Short and Optimal Duration of Dual Antiplatelet Therapy After ... — www.acc.org — https://www.acc.org/latest-in-cardiology/clinical-trials/2019/03/17/00/01/stopdapt-2
18. New trial evidence on the use of blood thinners after coronary stenting — www.escardio.org — https://www.escardio.org/news/press/press-releases/New-trial-evidence-on-the-use-of-blood-thinners-after-coronary-stenting
19. Short-Term DAPT After DES in Patients With ACS - American College of Cardiology — www.acc.org — https://www.acc.org/latest-in-cardiology/journal-scans/2024/10/14/18/17/short-term-dual-antiplatelet
20. [PDF] Bayesian Analysis - CDC Stacks — stacks.cdc.gov — https://stacks.cdc.gov/view/cdc/76956/cdc_76956_DS1.pdf
21. Sex Differences in the Safety and Efficacy of Different Durations of DAPT After PCI — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacadv.2024.101543
22. Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2021.08.074
23. 1-Month or 3-Month DAPT in Women and Men at High Bleeding Risk Undergoing PCI — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jcin.2025.01.424
24. Antithrombotic Therapy in High Bleeding Risk, Part I: Percutaneous Cardiac Interventions — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jcin.2024.08.022

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.